Pharmacokinetics Services Market (2026 - 2033)

Pharmacokinetics Services Market Summary

The global pharmacokinetics services market size was valued at USD 2.0 billion in 2025 and is projected to grow from USD 2.1 billion in 2026 to USD 3.6 billion in 2033, at a CAGR of 7.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.0% in 2025. Poor pharmacokinetics (PK) of therapeutics is one of the key reasons for higher drug attrition. To mitigate this challenge, researchers are integrating PK evaluations of novel molecular entities at every stage of the drug development stage.

Implementing predictive preclinical pharmacokinetics/ pharmacodynamics (PK/PD) models in various clinical trial stages is a promising way to address major bottlenecks in the pharmaceutical development process. This is primarily owing to PK studies identify potential challenges early and assist in required modifications and other development strategies to mitigate drug development challenges.

Increasing awareness among physicians, surgeons, and patients about the advantages of pharmacokinetic and toxicological studies to address various issues such as human equivalent doses and no observed effect levels services has boosted the market. Over the past decades, PK has gained significant prominence in drug discovery. Having understood the role of pharmacokinetics in pharmaceutical development, government and regulatory bodies are undertaking focused efforts to standardize pharmacokinetic protocols.

In the past years, regulatory requirements for clinical pharmacokinetic data have been progressively evolving to address the drug candidate's safety implications. PK study determines the initial amount of dosage that can be administered to study the therapeutic effects as well as potential side effects of the drug. This factor has played a vital role in reshaping this market. PK/PD analysis has helped progress drug development from preclinical studies to rapid and efficient in-man studies. The use of human in vivo and in vitro models for studying pharmacokinetics variability in the clinical development phase has been demonstrated for various pharmaceuticals. During drug development, phase I trials are the first opportunity to study the PK of a drug. They are performed on patients with cancer or healthy volunteers and are designed to determine an acceptable and safe dose for the later stages of clinical trials.

The gradual evolution of drug development into sound pharmacology has prompted several companies to broaden their service portfolio to maintain their competitive edge in the market. This is evident through the presence of a large number of companies with a broad service portfolio to serve various pharmaceutical development phases. Moreover, PK studies are interfacing with other drug discovery functions, such as toxicology, clinical pharmacology, and marketing. This interface has lucratively bolstered the adoption of PK services within the pharmaceutical industry. Certain limitations of in vitro PK studies, such as the inability of available experiments and protocols to predict complete interactions of target and drug candidate, are expected to hamper market growth during the forecast period.

Analyst Perspective

The pharmacokinetics services market is expected to experience significant growth driven by factors such as increasing adoption by drug manufacturers to identify poor Absorption, Distribution, Metabolism, and Excretion (ADME) as early as possible, benefits such as a reduction in the possibility of late-stage clinical trial failures, and expanding pipelines backed by increasing R&D activities. Advancements in biologics, biosimilars, cell and gene therapies have increased the demand for the pharmacokinetics services market. Talent scarcity, higher operational costs, data complexities, and logistical bottlenecks may pose challenges for this market. However, companies rely on strategies such as the adoption of Physiologically Based Pharmacokinetic (PBPK), portfolio expansions, strategic mergers and acquisitions, integration of value chains, and others to navigate through challenges.

Drug Type Insights

Small molecule dominated the market with a revenue share of more than 76.0% in 2025 and is expected to grow at the fastest CAGR over the forecast period. The segment’s growth can be attributed to high market penetration, growing market of generics, and their small size, which enables them to pass through the digestive tract easily, this means that the active substances can be absorbed into the bloodstream quickly and spread throughout the body. It uses chromatographic techniques combined with spectroscopic assays to study molecules of smaller atomic weight and drug metabolism and the amount of drug compounds in urine, blood, saliva, and tissue.

Although PK analysis for large molecules is estimated to hold a relatively smaller share in the pharmacokinetics services market than small molecules, this segment is anticipated to grow at a significant CAGR over the forecast period. This growth is majorly due to rising demand for biologics and biosimilars, which has prompted CROs to invest in broadening their PK analysis service portfolio for large moieties.

Large-molecule pharmacokinetic techniques include measurement of proteins, peptide interactions, and mostly greater weight molecules, such as IgE antibodies. They also include immunogenicity assays, Electrochemiluminescence (ECL) assays, vaccine potency support, and various other assays such as ELISA.

End Use Insights

The academic & government research institutes segment dominated the market with a market share of more than 45.0% in 2025, owing to extensive R&D public and private investment. Furthermore, the market is segmented into biotechnology & pharmaceutical companies, academic & government research institutes, and others.

Biotechnology and pharmaceutical companies segment is expected to grow at the fastest CAGR over the forecast period, owing to increased clinical trials due to the high prevalence of diseases. According to ClinicalTrials.gov, about 589,884 registered clinical studies are currently being conducted in all 50 states and in 226 countries and territories.

Application Insights

The small & medium enterprises segment dominated the market with a revenue share of around 59.0% in 2025, owing to government support through funding, various programs, and flexibility to take risks to fulfill customer needs and adapt to new technology. The market is segmented into small & medium enterprises and large enterprises.

The large enterprise segment is expected to grow at the fastest CAGR from 2026 to 2033, owing to increased demand for safer pharmaceutical drugs with higher absorption, distribution, metabolism, and excretion (ADME) rates. Moreover, the increasing prevalence of various diseases and the emergence of new ones, is expected to drive the demand for this segment further.

Regional Insights

North America dominated the market with a revenue share of more than 37.0% in 2025, owing to the presence of a large number of prominent pharmaceutical companies in the region. Several strategic alliances have been observed between major U.S.-based drug manufacturers and CROs that offer PK investigation services in the region. An effective regulatory structure of drug development processes, including PKPD and toxicology studies in the region, is one of the crucial factors enabling North America’s dominance.

Asia Pacific Pharmacokinetics Services Market Trends

Asia Pacific is estimated to expand at the fastest CAGR over the forecast period, owing to the perpetual business expansion of CROs in this region. Asian countries offer low operating and manufacturing costs compared to developed economies. Governments in developing economies such as China, India, Indonesia, and Taiwan are adopting policies to attract foreign investments to their manufacturing industries by reducing trade barriers and tariffs to create more employment opportunities. Moreover, there is a strong presence of potential subject bodies in Asia Pacific. These two factors are expected to drive the growth of pharmacokinetic services in Asian economies.

Key Pharmacokinetics Services Market Companies Insights

The pharmacokinetics services industry features a range of global, regional, and local players, making it a competitive market. The world’s leading companies are using partnerships, collaborations, acquisitions, mergers, and agreements as strategies to withstand the intense competition and increase their market share.

Key Pharmacokinetics Services Companies

The following key companies have been profiled for this study on the pharmacokinetics services market:

• Evotec SE

• Certara

• Pacific BioLabs, Inc

• Aragen Life Sciences Limited

• Medicilon USA Corporation

• Thermo Fisher Scientific Inc.

• Charles River Laboratories.

• Parexel International (MA) Corporation.

• Eurofins Discovery.

• Frontage Labs.

• SGS Société Générale de Surveillance SA.

• LGC Limited

• Creative Bioarray

Recent Developments

• In May 2026, SGS acquired Keystone Bioanalytical a specialized provider of bioanalytical testing services supporting the small and large molecule development.

• In January 2026, Certara, Inc., one of the key companies in model‑informed drug development, announced launch of AI‑powered module within Phoenix Cloud, its advanced suite. The module is newly developed to facilitate automation of pharmacokinetic (PK) report generation.

• In September 2025, Labcorp acquired Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses increasing its portfolio in oncology related clinical testing services.

Pharmacokinetics Services Market Report Scope

Global Pharmacokinetics Services Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmacokinetics services market report based on application, drug type, end use, and region:

• Drug Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Small Molecules

  • Large Molecules (Biopharmaceuticals)

• Application Outlook (Revenue, USD Billion, 2021 - 2033)

  • Small and Medium Enterprise

  • Large Enterprise

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Biotechnology & Pharmaceutical Companies

  • Academic & Government Research Institutes

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait